CTNI-66. ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Primary central nervous system lymphoma (PCNSL) is known as one of the incurable brain tumors. In March 2020, Tirabrutinib (TIR), a second-generation oral Bruton’s tyrosine kinase inhibitor, was approved for the indication of relapsed or refractory PCNSL (rrPCNSL) based on the results of a phase I/I...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Mishima, Kazuhiko, Narita, Yoshitaka, Nagane, Motoo, Terui, Yasuhito, Arakawa, Yoshiki, Yonezawa, Hajime, Asai, Katsunori, Fukuhara, Noriko, Sugiyama, Kazuhiko, Shinojima, Naoki, Aoi, Arata, Nishikawa, Ryo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Clinical Trials: Non-Immunologic
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650894/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.232
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi